PBAC Public Summary Documents – March 2024
Page last updated: 14 November 2025
Public Summary Documents relating to the March 2024 PBAC meeting.
- Adalimumab (uveitis): Injection 20 mg in 0.2 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled pen, Injection 80 mg 0.8 mL pre filled syringe, Injection 80 mg in 0.8 mL pre filled pen; Humira®
- Adalimumab (IMID): Injection 20 mg in 0.2 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled syringe, Injection 40 mg in 0.4 mL pre filled pen, Injection 80 mg in 0.8 mL pre filled syringe, Injection 80 mg in 0.8 mL pre filled pen; Humira® – March 2024 – December 2024 - July 2025
- Adalimumab: Injection 80 mg in 0.8 mL pre filled pen, Injection 80 mg in 0.8 mL pre filled syringe; Yuflyma®
- Amino Acid Formula Supplemented with Prebiotics, Probiotics and Long Chain Polyunsaturated Fatty Acids: Oral powder 400 g (Neocate Syneo); Neocate® Syneo
- Amino Acid Formula with Vitamins and Minerals without Phenylalanine: Oral liquid 125 mL, 30 (PKU Lophlex Select LQ); PKU Lophlex® Select LQ
- Amino Acid Formula with Vitamins, Minerals and Long Chain Polyunsaturated Fatty Acids without Phenylalanine: Oral powder 400 g (PKU Start); PKU Start™
- Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL; Saphnelo®
- Atezolizumab: Solution for subcutaneous injection containing atezolizumab 1875 mg in 15 mL; Tecentriq® SC
- Avacopan: Capsule 10 mg; Tavneos®
- Beclometasone with Formoterol: Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose; Fostair®
- Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Vegzelma®
- Bimekizumab (PsA): Injection 160 mg in 1 mL single use pre filled syringe, Injection 160 mg in 1 mL single use pre filled pen; Bimzelx®
- Bimekizumab (AS): Injection 160 mg in 1 mL single use pre filled syringe, Injection 160 mg in 1 mL single use pre filled pen; Bimzelx®
- Bimekizumab (nr‑axSpA): Injection 160 mg in 1 mL single use pre filled syringe, Injection 160 mg in 1 mL single use pre filled pen; Bimzelx®
- Brentuximab Vedotin: Powder for I.V. infusion 50 mg; Adcetris®
- Budesonide: Capsule (enteric) 3 mg; Budenofalk®
- Bulevirtide: Powder for injection 2 mg; Hepcludex
- Cabozantinib (clear cell RCC): Tablet 20 mg, Tablet 40 mg; Cabometyx®
- Cabozantinib (non-clear cell RCC): Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
- Cabozantinib (DTC): Tablet 20 mg, Tablet 40 mg, Tablet 60 mg; Cabometyx®
- Cetuximab: Solution for I.V. infusion 100 mg in 20 mL, Solution for I.V. infusion 500 mg in 100 mL; Erbitux®
- Dabrafenib and Trametinib: Dabrafenib: Capsule 50 mg (as mesilate), Capsule 75 mg (as mesilate), Tablet (dispersible) 10 mg; Tafinlar®; Trametinib: Tablet 500 micrograms, Tablet 2 mg, Powder for oral solution 5 micrograms per mL (as dimethylsulfoxide), 97 mL; Mekinist® – March 2024 – December 2024
- Dapagliflozin with Sitagliptin: Tablet containing dapagliflozin 10 mg with sitagliptin 100 mg; Sidapvia®
- Dupilumab: Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent®
- Edaravone: Solution concentrate for injection I.V. infusion 30 mg in 20 mL; Radicava®
- Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor: Pack containing 56 sachets containing granules elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 sachets containing granules ivacaftor 75 mg, Pack containing 56 sachets containing granules elexacaftor 80 mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets containing granules ivacaftor 59.5 mg; Trikafta®
- Empagliflozin: Tablet 10 mg; Jardiance®
- Etrasimod: Tablet 2 mg; Velsipity®
- Evolocumab: Injection 140 mg in 1 mL single use pre filled pen, Injection 420 mg in 3.5 mL single use pre filled cartridge; Repatha®
- Ibrutinib: Capsule 140 mg, Tablet 280 mg, Tablet 420 mg; Imbruvica®
- Icosapent Ethyl: Capsule 1 g; Vazkepa®
- Influenza Vaccine: Injection 0.5 mL; Flucelvax® Quad
- Influenza Vaccine: Injection 0.5 mL; Flublok® Quadrivalent
- Irinotecan (nanoliposomal): Solution for I.V. infusion containing nanoliposomal irinotecan (as sucrosofate) 43 mg in 10 mL; Onivyde®
- Larotrectinib: Capsule 25 mg (as sulfate), Capsule 100 mg (as sulfate), Oral solution 20 mg per mL (as sulfate), 50 mL, 2; Vitrakvi®
- Lebrikizumab: Injection 250 mg in 2 mL single use autoinjector; Ebglyss®
- Levodopa with Carbidopa and Entacapone: Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mL; Lecigon®
- Mepolizumab: Powder for injection 100 mg, Injection 100 mg in 1 mL single dose pre filled pen: Nucala®
- Migalastat: Capsule containing migalastat hydrochloride 150 mg; Galafold® – March 2024 – May 2024
- Nivolumab (NSCLC): Injection concentrate for I.V. infusion 100 mg in 10 mL, Injection concentrate for I.V. infusion 40 mg in 4 mL; Opdivo®
- Ofatumumab: Solution for injection 20 mg in 0.4 mL pre filled pen; Kesimpta®
- Osilodrostat: Tablet 1 mg, Tablet 5 mg; Isturisa®
- Prasugrel: Tablet 5 mg, Tablet 10 mg; Prasugrel SCP™
- Relugolix with Estradiol and with Norethisterone Acetate:Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg; Ryeqo®
- Respiratory Syncytial Virus Vaccine: Injection 0.5 mL; Abrysvo® – March 2024 – May 2024
- Rimegepant: Tablet (orally disintegrating) 75 mg; Nurtec® ODT
- Risperidone: I.M. injection (modified release), set containing 1 pre filled syringe powder for injection 75 mg and 1 pre filled syringe diluent 383 microlitres, I.M. injection (modified release), set containing 1 pre filled syringe powder for injection 100 mg and 1 pre filled syringe diluent 490 microlitres; Okedi®
- Romosozumab: Injection 105 mg in 1.17 mL single use pre filled syringe; Evenity®
- Selumetinib: Capsule 10 mg, Capsule 25 mg; Koselugo®
- Siponimod: Tablet 1 mg (as hemifumarate); Mayzent®
- Sodium Zirconium Cyclosilicate: Sachet containing powder for oral suspension (as hydrate) 5 g, Sachet containing powder for oral suspension (as hydrate) 10 g; Lokelma®
- Tadalafil: Tablet 20 mg; Tadalis
- Talazoparib: Capsule 0.1 mg, Capsule 0.25 mg, Capsule 0.35 mg, Capsule 0.5 mg; Talzenna®
- Tiotropium: Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate); Tiotropium Lupin
- Tofacitinib: Tablet (modified release) 11 mg; Xeljanz® XR
- Trastuzumab Deruxtecan: Powder for I.V. infusion 100 mg; Enhertu®
- Ustekinumab: Injection 45 mg in 0.5 mL single use pre filled syringe, Injection 45 mg in 0.5 mL single use pre filled pen, Injection 90 mg in 1 mL single use pre filled syringe, Injection 90 mg in 1 mL single use pre filled pen; Stelara®
- Ustekinumab: Injection 45 mg in 0.5 mL, Injection 45 mg in 0.5 mL single use pre filled syringe, Injection 90 mg in 1 mL single use pre filled syringe, Solution for I.V. infusion 130 mg in 26 mL; Wezlana®
- Vedolizumab: Injection 108 mg in 0.68 mL single use pre filled pen, Powder for injection 300 mg; Entyvio®
The following Public Summary Documents have been updated:
